Navigation Links
US Oncology Commends Governor Sebelius' Confirmation as U.S. Secretary of Health and Human Services
Date:4/28/2009

Kansas Governor a Strong Choice Due to Experience in Navigating Complex Health Care Access Issues, Working Across Party Lines to Promote Reform

WASHINGTON, April 28 /PRNewswire-USNewswire/ -- US Oncology, which supports one of the nation's largest cancer treatment and research networks representing approximately 1,200 oncologists nationwide, applauds today's Senate confirmation of Kansas Governor Kathleen Sebelius as U.S. Secretary of Health and Human Services (HHS).

"US Oncology is pleased to see Secretary Sebelius take the helm of national health care reform and push for new methods to address the current obstacles restricting access to quality health care for all -- particularly for the more than 10 million Americans now living with cancer," said Roy Beveridge, M.D., Chairman of the US Oncology Public Policy Steering Committee. "We look forward to working closely with Sec. Sebelius and her colleagues to create practical, enduring solutions that address our system challenges while always first advancing the needs of America's cancer patients."

Prior to her appointment as Secretary, Gov. Sebelius established a record of working in a bipartisan manner to promote health care reform during her eight years as Governor and six years as Kansas' insurance commissioner, and helped draft a national patients' bill of rights during her work as commissioner. As HHS Secretary, she will lead the federal government's largest domestic department, overseeing the Centers for Medicare and Medicaid Services (CMS), the Food and Drug Administration (FDA), the National Institutes of Health (NIH) and other key health care decision-making agencies.

"Secretary Sebelius will play a chief role in promoting the advancement of sweeping reform measures and technological innovations designed to improve care delivery while lowering costs, such as President Obama's priority to expand the use of heal
'/>"/>

SOURCE US Oncology
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Compendia Bioscience Announces Collaboration with MDS Pharma Services to Deliver Novel Solution for Oncology Drug Development
2. Pharmatech Oncology Launches New Data Management Business Unit
3. Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
4. Pathwork Tissue of Origin Test Validation Study Published in Journal of Clinical Oncology
5. US Oncology Wins Three National Safety Council Awards
6. Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City
7. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
8. Radiation Oncology Institute (ROI) Campaign Raises $7 Million
9. House Bill to Improve Accuracy of Medicare Reimbursement Introduced: Members of Congress Seek to Stem Growing Healthcare Coverage Shortfalls, Community Oncology Alliance Advocates for Swift Passage of Bill
10. ACORNs Success in Delivering Top Quality Research Portfolio to Community-Based Oncology Practices Presented at Annual Investigator Meeting
11. US Oncology Reports Fourth Quarter and Yearend 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)... Youngest Babies, This Type of Blood Cancer Is Most ... 5 Pediatric oncologists have identified specific genes, dubbed ... an often-fatal form of leukemia in infants. By more ... predict which infants may benefit from particular treatments. ...
(Date:12/5/2009)... ,something,s wrong with being single, myth , , SATURDAY, Dec. 5 ... their 40th birthday without ever tying the knot, since research ... married folks. And, um, isn,t there something wrong with those ... A new study looking at psychological measures shows that never-married ...
(Date:12/5/2009)... by the National Association of Certified Professional Midwives ... for Midwifery (CfM), International Center for Traditional Childbearing ... the Midwifery Education Accreditation Council (MEAC). To ... Campaign to secure federal recognition of CPMs language ...
(Date:12/4/2009)... Care Investment Trust Inc. (NYSE: CRE ... Directors has declared a dividend of $0.17 per share of common ... common shareholders of record on December 14, 2009. ... Inc. is a real estate investment and finance company investing in ...
(Date:12/4/2009)... World Assurance,Company Holdings, Ltd (NYSE: AWH ) ... and Jack Sennott, Executive Vice,President and Chief Corporate Strategy ... Financial Services Conference being held at the Goldman,Sachs Conference ... 2009. ,, About Allied World ...
Breaking Medicine News(10 mins):Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2
... to recent rises in caesarean section rates, according to ... University. , The findings come from an analysis of ... team under Professor Gordon Smith, at the University,s Department ... more than 500,000 entries collected by the Scottish Morbidity ...
... depression, drug abuse, study says , , WEDNESDAY, July 2 ... in "sacred mushrooms" can last more than a year, ... investigations may lead to new ways to help people ... , In a previous study, the researchers gave psilocybin ...
... Inc.,(Nasdaq: SUPG ), a pharmaceutical company dedicated ... for solid tumors and,hematological malignancies, today announced that ... is scheduled to present at the,Collins Stewart Growth ... Oriental Hotel in New York City., SuperGen,s ...
... CLARA, Calif., July 2 Align Technology,Inc. (Nasdaq: ... proprietary method of,straightening teeth without wires and brackets, ... 2008 financial results on Tuesday, July,29, 2008, after ... released,over PR Newswire and First Call and will ...
... 2 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX:,CUR), a life ... laboratory services, announced today that Dr. Timothy,J. Holzer, ... Dr. Scott,Waldman, from Thomas Jefferson University, were speakers ... session at the Eastern Cooperative Oncology,Group (ECOG), one ...
... Toronto Stock Exchange Symbol: CYT, MONTREAL, ... CYT), the global leader in cryotherapy products ... of Frank Vandeputte as Vice,President, Europe. Based ... Netherlands, Mr. Vandeputte will be responsible for ...
Other Medicine News:Health News:Major rise in Caesarean sections linked to impaired womb function with age 2Health News:Hallucinogen Gives Lasting Spiritual Boost 2Health News:SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008 2Health News:Align Technology to Announce Second Quarter Fiscal 2008 Results on July 29 2Health News:DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group 2Health News:DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group 3Health News:CryoCath Appoints Vice President, Europe 2
(Date:12/4/2009)... Dec. 4 Drs. Neal Shore and E. David ... the additional analysis of secondary end points of biochemical ... FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in ... Prostate cancer patients who received FIRMAGON 240/80 mg/month ...
(Date:12/4/2009)... (NYSE: AZN ) today announced that the ... SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive ... Disorder (MDD). SEROQUEL XR is the only medication in ... major depressive disorder as adjunctive therapy and acute depressive ...
(Date:12/3/2009)... , a leading primary research firm, today announced the launch ... that monitors and projects trends and market share in the ... captures actual patient usage for 87 different Sleep Apnea mask ... providers going back to January 2006. In the most ...
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2German Alliance for Industrial Biotechnology Debuts in Montreal 12992 1German Alliance for Industrial Biotechnology Debuts in Montreal 12992 2Sparta Systems TrackWise 28R 29 Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 12990 1Sparta Systems TrackWise 28R 29 Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 12990 2Sparta Systems TrackWise 28R 29 Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 12990 3Sparta Systems TrackWise 28R 29 Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 12990 4Dynamic molecular mechanism to keep brain activity stable 51464 1
... SEATTLE, Aug. 22 Vical Incorporated (Nasdaq:,VICL) announced ... vaccine Phase 2a,clinical trials, using a plasmid DNA ... and manufactured by Vical, reinforced previously,reported Phase 1 ... was safe and well-tolerated, and was effective in ...
... Trial Examines Single, Higher, More Concentrated Dose of ... ... Nuvelo, Inc.,(Nasdaq: NUVO ) today announced enrollment of the ... with,Mini-dose Alfimeprase-3) trial evaluating lead product candidate,alfimeprase, for the treatment of ...
Other Medicine Technology:Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 2Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 3Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 2Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 3Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 4
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor....
Shandon HistoWave is the answer to rapid tissue processing. It reduces time for fixation, tissue processing, decalification, immunochemistry and special stains....
The HypercleanTM 1 is a versatile, durable fume handling station. The Hyperclean 1 fume handling station unit comes complete with one (1) blower unit and one (1) charcoal filter....
... 2 fume containment system ... benchtop equipment. Even large ... inside the Hyperclean 2. ... system unit comes complete with ...
Medicine Products: